Objectives: This study aims to determine the minimum pericardial fluid volume necessary for adequate cytologic diagnosis.
Results: The malignancy fraction increased from 6.5% for specimens 10 mL or less to 20.7% for more than 600 mL (P ¼ .03). While the cumulative malignancy fraction was 18.1% above a cutoff of 60 mL, it was 10.6% below this threshold (P ¼ .03). The sensitivity of cytology compared with pericardial biopsy was 70.0% for 60 mL or less and 91.1% for more than 60 mL (P ¼ .14).
Conclusions: Small-volume pericardiocentesis specimens detect fewer malignancies and have inferior sensitivity compared with pericardial biopsy. A volume of more than 60 mL should be submitted to cytology to ensure adequate diagnosis of pericardial fluids.
Pericardial effusions occur as a complication of both benign and malignant conditions. Even among oncology patients, more than 50% of pericardial effusions arise through benign mechanisms, including infection, toxicity from radiation or chemotherapy, and lymphatic obstruction. 1, 2 But direct involvement of the pericardium by malignancy portends a significantly worse prognosis, with a median survival of less than 5 months in most studies. [3] [4] [5] [6] [7] Moreover, malignant pericardial effusion can be the first presentation of cancer in a small fraction of patients. [8] [9] [10] Consequently, it is essential to quickly and accurately identify malignant pericardial effusions to initiate appropriate treatment. Cytologic evaluation is well established as the gold standard for diagnosis of malignant pericardial effusions, with a sensitivity of 71% to 100%. 2, 8, [11] [12] [13] This sensitivity is markedly superior to the 55% to 64% reported for pericardial
Upon completion of this activity you will be able to:
• describe the potential etiologies and implications of pericardial effusions in oncology patients.
• discuss the relationship between fluid volume submitted and detection of malignancy in pericardial effusion specimens.
• consider strategies for dealing with low-volume pericardial effusion specimens.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit TM per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
Exam is located at www.ascp.org/ajcpcme.
biopsy, 11, [13] [14] [15] [25] [26] [27] This variable has never been formally assessed in pericardial effusions.
In this study, we sought to determine whether specimen volume influences cytologic evaluation of pericardiocentesis specimens. We also aimed to identify a minimum cutoff volume to provide practical guidance for how much fluid needs to be submitted for ideal cytologic results.
Materials and Methods

Case Selection
The Johns Hopkins Medicine Institutional Review Board X granted approval for this study (study number NA_00089398). Thereafter, the electronic pathology database was searched for all pericardial fluids analyzed at our institution between January 1, 1994, and December 31, 2013. A total of 660 pericardial effusion specimens were identified. Only specimens that were processed in the Jack K. Frost Cytopathology Laboratory and had a numeric volume recorded were included in this study. Of the original 660 specimens, 180 were excluded because of nonnumeric or absent volume measurements. Thus, 480 pericardial fluids were included in the data set. These specimens included pericardial fluids obtained through both percutaneous and surgical drainage.
Cytopathology
Specimens were processed following standard procedures in the Clinical Laboratory Improvement Amendmentscertified cytopreparatory laboratory. Pericardial fluids were received fresh or after refrigeration overnight without fixation. If more than 100 mL was received, specimens were agitated to homogenize cellularity, and a representative 100-mL aliquot was processed. If 100 mL or less was received, the entire specimen was processed. Samples were divided into two 50-mL centrifuge tubes and centrifuged on a Hettich centrifuge (Hettich Instruments, Tuttlingen, Germany) for 10 minutes at 1,830 rpm. The cell concentrate from the first tube was resuspended with a balanced salt solution, and two to eight slides were prepared using the Cytospin method (Thermo Fisher Scientific, Waltham, MA) and Papanicolaou staining. The pellet from the second tube was fixed in formalin for 30 minutes before histologic processing as a cell block and H&E staining.
Data Processing
Cytologic diagnoses for each specimen were retrospectively reviewed and categorized as benign, malignant, atypical (not definitively benign or malignant, including those suspicious for malignancy), or nondiagnostic (obscured by blood or insufficiently cellular for any diagnosis). Specimen volume received, cancer subtype, and patient demographics were tabulated. Corresponding procedure notes were identified in the electronic medical record, and all available preoperative diagnoses and original fluid volumes drained were recorded. The pathology database was also searched for additional cytopathology and surgical pathology specimens from study patients, and any previous or concurrent diagnosis of malignancy at our institution was documented. Results of pericardial biopsy taken within 6 months of the effusion of record were noted.
Data Analysis
For simplicity of analysis, the data set was divided by volume into six bins designed to maintain approximately equal numbers and correspondence to common specimen volumes. These bins were drawn at 10 mL or less, 11 to 20 mL, 21 to 60 mL, 61 to 300 mL, 301 to 600 mL, and 601 mL or more and contained 46, 27, 87, 96, 118, and 106 specimens, respectively. These bins were then combined into larger groups above and below various cutoff points to determine the minimum threshold volume. Statistical analysis was performed on the original bins, larger groups, and data set as a whole. The subset of effusions with an accompanying pericardial biopsy was also analyzed separately.
Mean volumes were compared across diagnostic categories and clinical and demographic subgroups using a twotailed Student t test. Diagnostic accuracy for each volume bin and group was estimated using the malignancy fraction-the percentage of specimens that received a malignant diagnosis. A 95% confidence interval was also calculated for each malignancy fraction. Malignancy fractions from different bins and groups were compared using the Fisher exact test. Sensitivity of pericardial cytology and biopsy was calculated for the subset of patients who had both tests performed. All statistical analysis was performed using the statistical programming language R (R Foundation, Vienna, Austria; r-project.org).
Results
The 480 pericardial effusions in this data set represented 441 individual patients, including 230 females and 211 males. Patients had a mean (SD) age of 49.0 (18.6) years (range, 0-86 years). Of these patients, 190 (43.1%) had a previous diagnosis of malignancy that had been pathologically confirmed at our institution. This subset of patients included 104 females and 86 males, with a mean (SD) age of 49.7 (17.6) years (range, 0-80 years). As shown in Table 1 , 56 distinct tumor subtypes were represented; the most common categories of cancer were lung carcinoma, leukemia, lymphoma, and breast carcinoma. The clinical preoperative diagnosis favored a malignant effusion in 195 (40.6%) cases, 177 of which came from patients with a previous pathologically confirmed cancer. As shown in Table  2 , the remaining 285 cases had a wide range of benign preoperative diagnoses, most commonly including surgical complications, infectious pericarditis, and collagen vascular disease.
The diagnoses of the 480 pericardial specimens are summarized in Table 3 ; 327 (68.1%) received benign diagnoses, 75 (15.6%) were malignant, 60 (12.5%) demonstrated atypical features, and 18 (3.8%) were nondiagnostic. Among the malignant effusions, 21 specific tumor subtypes were diagnosed. The most common categories of cancer included lung carcinoma, breast carcinoma, lymphoma, and leukemia, similar to patients' histories. The malignancy fraction was significantly higher in patients with previous cancer than those without such history (30.7% vs 3.7%; P < .001; odds ratio [OR], 11.4; 95% confidence interval [CI], 5.6-25.6). The malignancy fraction also varied across cancer subtypes, with the highest likelihood of malignant pericardial effusion in patients with ovarian carcinoma (75.0%), breast carcinoma (65.0%), carcinoma of unknown primary (60.0%), and pancreatic carcinoma (50.0%).
Clinical information on the volume removed at the time of pericardiocentesis was available for 434 specimens. The mean (SD) volume drained was 675 (417) mL (range, 10-2,600 mL). In contrast, the mean (SD) volume received in cytology was 335 (345) mL (range, 1-2,500 mL), a significantly smaller quantity (P < .001; 95% CI, 290-390 mL). A mean (SD) percentage of 52.4% (34.2%) of fluid drained was submitted to cytology (range, 0.1%-100%). Volumes received in cytology did covary with some demographic features. Males had significantly larger effusions than females (380 vs 292 mL; P ¼ .006; 95% CI, 25-150 mL), and adults had significantly larger effusions than children (356 vs 35 mL; P < .001; 95% CI, 284-357 mL). However, there was not a significant difference in volume between patients with or without previous pathologically confirmed malignancy (304 vs 358 mL; P ¼ .08; 95% CI, -7 to 115 mL) or with malignant or benign preoperative diagnoses (318 vs 346 mL; P ¼ .37; 95% CI, -89 to 33 mL).
Malignancy was diagnosed in specimens with received volumes from 3 to 1,500 mL. The mean volume of malignant specimens did not significantly differ from that of all other groups. However, as shown in Figure 1 , the malignancy fraction increased consistently with volume across all volume bins. Notably, there was a significant increase in the malignancy fraction from the lowest bin of 10 mL or less to the highest bin of more than 600 mL (6.5% vs 20.8%; P ¼ .03; OR, 3.72; 95% CI, 1.03-20.53). This study did not have sufficient power to detect significant differences in volumes between consecutive volume bins. However, when bins were combined into larger groups to determine an optimal cutoff point Table 4 , there were significantly more malignancies diagnosed at more than 60 mL compared with 60 mL or less (10.6% vs 18.1%; P ¼ .03; OR, 1.86; 95% CI, 1.02-3.54). In this series, 130 effusions had a corresponding pericardial biopsy specimen taken within 6 months of cytologic diagnosis, of which 106 were benign and 24 malignant. Ten patients had malignant cytology but benign biopsy, while five patients had benign cytology but malignant biopsy. Among the 34 patients who had both tests performed and received a malignant diagnosis by at least one modality, the overall sensitivity of effusion cytology for diagnosing malignancy was 85.3%, while the sensitivity of pericardial biopsy was 70.6%. Although the small sample size limited the statistical power, there was a substantial difference in sensitivity of effusion cytology between small-and large-volume specimens, with a 70.0% sensitivity in specimens 60 mL or less and 91.7% sensitivity in specimens more than 60 mL (P ¼ .14; OR, 4.46; 95% CI, 0.42-63.88).
The ability of cytopathology to confirm the clinical impression differed across the 60-mL threshold. Among patients with a preoperative suspicion of malignant pericardial effusion and a volume of 60 mL or less, only 17 received a confirmatory cytologic diagnosis. However, 53 patients with the same clinical suspicion but with specimen volumes more than 60 mL received a confirming diagnosis (25.0% vs 40.5%; P ¼ .04; OR, 2.03; 95% CI, 1.01-4.25). There was also a difference in the frequency of cytologic diagnoses of malignancy made in patients with benign preoperative diagnoses across this cutoff. Only one such unexpected malignancy was identified at volumes of 60 mL or less, while five were diagnosed at volumes of more than 60 mL (1.0% vs 2.6%). The rarity of this phenomenon limited the statistical significance and power of these findings.
Discussion
Effusion cytology is well established to be the most sensitive means of identifying malignant pericardial effusions, but it is not yet clear whether the results of cytologic analysis are equally valid for small-and large-volume pericardial effusion specimens. Recent studies in pleural fluids have demonstrated that a minimum volume of 25 to 75 mL is necessary for adequate cytologic diagnosis. [25] [26] [27] However, to our knowledge, the question of volume has never been addressed in pericardiocentesis specimens. In this study, we analyzed 480 pericardial effusions collected over a 20-year period to determine the impact of specimen volume on diagnosis of malignancy. This study not only represents the first formal evaluation of adequate volume in pericardial effusions but also is one of the largest series of pericardial fluids reported to date.
Overall, this study determined that the volume of fluid submitted to cytology does have a profound influence on the diagnosis of malignancy. There was no inherent difference in the mean volume of malignant and nonmalignant fluids submitted to cytology in our data set. However, pericardial fluid specimens were much more likely to receive a malignant diagnosis at large volumes than they were at small volumes. The malignancy fraction increased steadily from 6.5% among specimens 10 mL or less to 20.8% in specimens more than 600 mL-a statistically significant difference. This disparity occurred across a patient population that was statistically equivalent other than volume submitted for cytologic analysis, suggesting that low-volume specimens were primarily responsible for the smaller proportion of malignancies identified.
More specifically, this study demonstrated that a cutoff of 60 mL provides an optimal minimum threshold for adequate evaluation of pericardial fluid specimens. The sensitivity of effusion cytology for fluids 60 mL or less was 70.0%, slightly worse than that of pericardial biopsy, while the sensitivity at more than 60 mL was an impressive 91.7%. Moreover, there was a significantly better correlation between preoperative and cytologic diagnosis of malignancy above the 60-mL threshold. Overall, just 10.6% of specimens 60 mL or less received a malignant diagnosis, whereas 18.1% of those more than 60 mL were called malignant-almost a twofold difference. These results suggest that a higher volume specimen would need to be examined for just 14 specimens to make one additional diagnosis of cancer. If higher volumes had been submitted for all the specimens in our series, an additional 12 cancer diagnoses might have been made.
Obviously, original effusion size and patient safety considerations can limit the fluid volume submitted to cytology. However, our findings indicate that most pericardiocentesis specimens are large enough to meet this cutoff. While 160 (33.3%) fluids in our data set had 60 mL or less submitted to cytology, just 12 (2.8%) had 60 mL or less drained. Moreover, only half the volume drained was submitted to cytology on average, with less than 10% submitted in a quarter of cases. While some proportion was submitted for microbiologic cultures, fluid chemistry, and cell counts, these tests require less than 5 mL each for adequate analysis at our institution. As a result of these analyses, we are recommending that all remaining fluid after these studies be submitted to cytology. Unlike dissolved chemical analytes or microbial particulates, eukaryotic cells are only loosely suspended in effusion fluid and require vigorous homogenization or intentional sampling of the fluid that contains cells. This step is best done by trained laboratory technicians.
This study has at least two limitations. First, we were unable to determine if cytopathologists felt subjectively more confident making a definitive diagnosis of malignancy in large-volume specimens than small-volume specimens. While such bias is unlikely, we are unable to entirely rule it out in this retrospective analysis. Second, it is conceivable that malignancies inherently produce larger pericardial effusions than benign conditions. As the difference in true effusion size was negligible between diagnostic categories if the minimum adequate volume of 60 mL was analyzed in cytology, we also find this possibility unlikely. Moreover, this limitation does not detract from our central conclusion that submitting the maximum volume to cytology optimizes the diagnostic results.
Overall, the findings in our study demonstrate that more than 60 mL of pericardial fluid is necessary to ensure that a benign diagnosis is really benign. Cytology specimens with volumes more than 60 mL have a higher likelihood of receiving a malignant diagnosis, superior sensitivity compared with pericardial biopsy, and better correspondence to clinical impressions. Although these results need to be validated in other hospitals, we find it reasonable for cytopathology laboratories to add a disclaimer to all nonmalignant specimens 60 mL or less, raising the possibility that the low volume submitted may have compromised specimen evaluation. Moreover, we recommend that physicians submit the maximum amount of pericardiocentesis fluid possible for cytologic analysis whenever a cytologic diagnosis is sought.
